The Emory Alzheimer's Disease Research Center (ADRC) provides Georgia and the region with comprehensive clinical, research, and educational programs This renewal application outlines our success in building an environment that encourages and supports innovative projects directed at understanding the pathogenesis and developing new treatments for AD and other age-related cognitive disorders. We benefit from generous institutional support from Emory, one of the nation's fastest growing research academic enterprises, and collaborative interactions with the Emory Center for Neurodegenerative Disease, and the Yerkes National Primate Center. Our 5 cores demonstrate remarkable productivity in recruiting patients from the culturally diverse clinical specialty programs at Emory and Grady Memorial Hospitals for participation in our ADRC registry, the autopsy program, and the various clinical research activities. Data from these cores are captured and stored for distribution to local researchers and for national collaborations. Our biospecimen banks include well-characterized neuropathological case materials, and DNA, CSF, and blood samples from our clinical populations. These valuable resources are distributed widely for a variety of approved studies of genetic, molecular, pharmacological, and pathological investigations. The ADRC educational programs reach a broad audience of students, health care professionals, and the public. We propose three cutting edge research projects that are closely integrated with ADRC Cores: Project 1 (Dr. Ben Hampstead) """"""""Comparison of Memory Rehabilitation Techniques in Mild Cognitive Impairment"""""""", will use a novel approach to rehabilitation of memory combining behavioral components with functional brain imaging to address whether rehabilitation techniques target the intended brain regions and to determine the signature of brain activity associated with successful rehabilitation. Project 2, """"""""miRNA Expression Modulation of Alzheimer Disease Pathogenesis"""""""" (Dr. Peng Jin) will extend studies of miRNAs selectively altered in AD brain and evaluate their role in the post-transcriptional regulation of the expression of specific mRNAs that are involved in AD pathogenesis. Project 3, """"""""Norepinephrine-TrkB Interactions in Alzheimer's Disease"""""""" (Dr. David Weinshenker) studies a novel interaction between catecholamines and the TrkB receptor in animal and cell culture models of AD, as well as in brain tissues obtained from controls, MCI, and AD cases. Collectively, these projects span clinical, translational, and basic science research and will advance our understanding of cognition in normal aging and its transitions to mild cognitive impairment, AD, and related neurodegenerative disorders.

Public Health Relevance

Georgia has one of the fast growing elderly populations in the country, anticipating a major increase in AD and other age-related neurodegenerative conditions in the decades ahead. Advances in clinical care, research, and education are essential to successfully confront the challenge. Renewal of the Emory ADRC will sustain progress in better understanding disease pathogenesis, enable earlier identification of at-risk individuals, and catalyze development of more effective treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG025688-10
Application #
8662642
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J2))
Program Officer
Phelps, Creighton H
Project Start
2005-06-01
Project End
2015-04-30
Budget Start
2014-08-15
Budget End
2015-04-30
Support Year
10
Fiscal Year
2014
Total Cost
$1,499,974
Indirect Cost
$532,249
Name
Emory University
Department
Neurology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Zhang, Yuhai; Zhou, Xiao-Hua; Meranus, Dana H et al. (2016) Benzodiazepine Use and Cognitive Decline in Elderly With Normal Cognition. Alzheimer Dis Assoc Disord 30:113-7
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-9
Holler, Christopher J; Taylor, Georgia; McEachin, Zachary T et al. (2016) Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia. Mol Neurodegener 11:46
LeVine 3rd, Harry; Walker, Lary C (2016) What amyloid ligands can tell us about molecular polymorphism and disease. Neurobiol Aging 42:205-12
Forrester, Sarah N; Gallo, Joseph J; Smith, Gwenn S et al. (2016) Patterns of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Risk of Dementia. Am J Geriatr Psychiatry 24:117-25
Buijsen, R A M; Visser, J A; Kramer, P et al. (2016) Presence of inclusions positive for polyglycine containing protein, FMRpolyG, indicates that repeat-associated non-AUG translation plays a role in fragile X-associated primary ovarian insufficiency. Hum Reprod 31:158-68
Rui, Yanfang; Zheng, James Q (2016) Amyloid β oligomers elicit mitochondrial transport defects and fragmentation in a time-dependent and pathway-specific manner. Mol Brain 9:79
White, Matthew T; Shaw, Leslie M; Xie, Sharon X et al. (2016) Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease. J Alzheimers Dis 51:463-70
Seyfried, Nicholas T; Dammer, Eric B; Swarup, Vivek et al. (2016) A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease. Cell Syst :
Hampstead, B M; Khoshnoodi, M; Yan, W et al. (2016) Patterns of effective connectivity during memory encoding and retrieval differ between patients with mild cognitive impairment and healthy older adults. Neuroimage 124:997-1008

Showing the most recent 10 out of 293 publications